No change of infliximab levels in stored blood for preoperative autologous blood donation: a preliminary report
No change of infliximab levels in stored blood for preoperative autologous blood donation: a preliminary report
复制标题
术前自体献血储存血液中英夫利昔单抗水平没有变化：初步报告
DOI：
10.3109/s10165-005-0404-z
复制
发表时间：
2005
影响因子：
2.2
通讯作者：
T. Matsushita
中科院分区：
文献类型：
--
作者：
K. Nishimura;N. Wakimoto;J. Sasahara;C. Yanagisawa;F. Eda;J. Nishino;Hidekazu Tomiyama;T. Matsushita
在最近广泛使用英夫利昔单抗治疗类风湿性关节炎（RA）的同时，我们遇到了必须在使用该药物的情况下进行全关节置换术的患者。由于术前自体献血（PABD）是日本全关节手术期间和术后失血对策的主要手段，因此在我国存在英夫利昔单抗可能残留在捐献血液中的可能性。如果储存的血液中存在高浓度的英夫利昔单抗，输注此类血液可能会导致与该药物相关的不良事件，包括感染。然而，英夫利昔单抗在储存血液中的血流动力学尚不清楚，尽管血清中的血流动力学是众所周知的。因此，本研究的目标是阐明为 PABD 储存的血液中英夫利昔单抗的血液动力学。然而，由于在实现该目标的过程中获得了一些非常有趣的数据，因此我们将它们作为初步报告在此呈现。
Concurrent with the recent wide use of infliximab for rheumatoid arthritis (RA), we are encountering patients in whom total joint arthroplasties must be performed under the administration of this agent. Because preoperative autologous blood donation (PABD) is the mainstay of countermeasures against blood loss during and after total joint surgery in Japan, the possibility arises in our country that infliximab may remain in the donated blood. If high levels of infliximab are present in the stored blood, transfusion of such blood may cause adverse events, including infection, related to the agent. Nevertheless, the hemokinetics of infliximab in stored blood are not known, although those in serum are well known. The goal of the current study was, therefore, to clarify the hemokinetics of infliximab in blood stored for PABD. However, because some very interesting data were obtained on the way to that goal, we present them here as a preliminary report.